FDA Breakthrough Device Designation
XCath Robotics, a medical‑device company focused on endovascular surgical robotics, received Breakthrough Device Designation from the U.S. Food and Drug Administration for its Iris Surgical Robotic System, which is intended for remote robotic‑assisted mechanical thrombectomy in patients with acute ischemic stroke. The FDA’s Breakthrough Devices Program is designed to expedite development of devices that could provide more effective treatment for life‑threatening or debilitating conditions, and the designation grants XCath increased interaction with FDA experts throughout the regulatory review process.
Operational Milestone – Operation Robo Angel
In March 2026, XCath achieved the world’s first remote telerobotic mechanical thrombectomy during a clinical investigation named Operation Robo Angel. Renowned neurosurgeon Dr. Vitor Mendes Pereira operated the Iris System from a control station in Santiago, Panama, to treat a patient located more than 120 miles away at The Panama Clinic in Panama City. This demonstration proved that specialist physicians can perform thrombectomy procedures remotely, potentially overcoming geographic barriers to stroke care.
Stroke Burden and Access Gaps in India
Stroke is the fourth leading cause of death in India, accounting for approximately 700,000 deaths each year and representing 10 % of the global stroke burden. Cases have risen 51 % over the past three decades. It is estimated that over 270,000 Indian patients are annually eligible for mechanical thrombectomy, yet only 1,000‑2,000 procedures are performed nationwide. Only about 20 % of the population lives within one hour of a stroke centre capable of thrombectomy, and 55 % of stroke and cardiac deaths are attributed to delays in seeking care. For patients with large‑vessel‑occlusion (LVO) strokes, 77 % either die or suffer severe disability without timely treatment. Globally, the median access rate to mechanical thrombectomy is just 2.79 %.
Corporate Outlook and Upcoming Communication
CEO Eduardo Fonseca stated that the FDA Breakthrough Designation is a key milestone for XCath’s mission to expand access to life‑saving stroke care for millions of patients. He emphasized continued collaboration with the FDA and the importance of real‑world learnings from investigational cases in shaping the system. XCath plans to release a documentary on Operation Robo Angel next month, highlighting the remote procedure’s potential impact.
Disclaimer
The press release is provided under an arrangement with Newsvoir; PTI assumes no editorial responsibility for its content.